We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Brain Stimulation for Depression

By HospiMedica staff writers
Posted on 17 Aug 2005
New research suggests that transcranial magnetic stimulation (TMS) may offer a less disruptive way to use electromagnetic energy against depression, schizophrenia, and other psychiatric disorders.

Electroconvulsive therapy (ECT) has been used in the past to treat depression and other psychiatric disorders but it can produce short-term confusion and memory loss, and patients require general anesthesia and muscle relaxants.

In contrast, TMS produces stimulation that is much milder and more localized than ECT. More...
An electrical generator produces a series of strong magnetic fields in a wire coil, which is mounted on a paddle and positioned on or near a patient's forehead or scalp. The fluctuating magnetic force produces an electrical current that influences neurons in the area directly under the coil. Moreover, the magnetic field can be applied to fully conscious patients, who feel no pain and can read and talk during treatment and drive home afterward. Memory is not affected.

More than 30 studies are now testing the potential of TMS for treating conditions such as stroke, Parkinson's disease, and cerebral palsy, according to the August 3, 2005, issue of the Harvard Mental Health Letter (Harvard Medical School; Boston, USA). The letter also reported that about 40% of patients with medication-resistant depression show some improvement after TMS. The findings on the effects of TMS on schizophrenia and post-traumatic stress disorder are mixed. A controlled study showed that TMS was no more effective than sham treatment for patients with obsessive-compulsive disorder.




Related Links:
Harvard Mental Health Letter

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.